Houghton K, Patil D, Gomez B, Feldman SR. Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of Secukinumab. Dermatol Ther. 2021 Aug;11(4):1373-84.


INTRODUCTION: Patients with psoriasis (PsO) experience impaired health-related quality of life due to physical and psychosocial burdens.

OBJECTIVE: To assess the correlation between change in Psoriasis Area and Severity Index (PASI) score and selected Dermatology Life Quality Index (DLQI) domain scores in patients with moderate-to-severe PsO and those with PsO and comorbid psoriatic arthritis (PsA).

METHODS: This post hoc analysis of four phase 3 clinical trials included patients with moderate-to-severe PsO randomized to secukinumab 150/300 mg, etanercept, or placebo. Pairwise latent growth models were applied to assess the longitudinal correlation between change in PASI scores and changes in 3 DLQI domain scores (daily activities, leisure activities, and symptoms/feelings). The initial (baseline to Week 12) and sustained (Week > 12 to Week 52) treatment exposures were analysed by population type (total, PsO only, and PsO with comorbid PsA) and treatment arm (secukinumab, etanercept, or placebo).

RESULTS: Among the total population (N = 2401), PASI change was positively correlated with change in each assessed DLQI domain; correlations were weak-to-moderate over the initial treatment exposure period (β range, 0.20-0.29; all P < 0.001) and moderate-to-strong over the sustained exposure period (β range, 0.63-0.69; all P < 0.001). Similar trends were observed regardless of the presence of comorbid PsA. These relationships were confirmed among patients treated with secukinumab, etanercept, or placebo.

CONCLUSIONS:
Improvements in PASI scores were directly moderately related to improvements in DLQI domain scores from initiation of treatment and extended over time, regardless of presence of comorbid PsA or treatment received.

Share on: